SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance

Cell Proliferation

Volumn 49, Issue 2, 2016, Pages 195-206

  Yu, Fengbo ^a   Li, Guihong ^b   Gao, Junxia ^a   Sun, Yuxue ^b   Liu, Pengfei ^b   Gao, Haijun ^b   Li, Peiwen ^b   Lei, Ting ^b   Chen, Yong ^b   Cheng, Ye ^b   Zhai, Xiao ^c   Sayari, Arash J ^d   Huang, Haiyan ^b   Mu, Qingchun ^a  

^a MUDANJIANG MEDICAL UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN KINASE B; SPOCK1 PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ALKYLATING AGENT; DACARBAZINE; PROTEOGLYCAN; SPOCK1 PROTEIN, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIZATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR INVASION; UPREGULATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN NEOPLASMS; CELL MOTION; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROTEOGLYCANS;

EID: 84959260407     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12241     Document Type: Article

References (25)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
2. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21, 1624-1636.
3. Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS et al. (2013) The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. J. Neurooncol. 112, 277-283.
4. Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R (2006) New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg. Focus 20, E6.
5. Zhang J, Stevens MF, Bradshaw TD (2012) Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 5, 102-114.
6. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P et al. (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20, 1375-1382.
7. Johannessen TC, Bjerkvig R (2012) Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev. Anticancer Ther. 12, 635-642.
8. Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I et al. (2006) Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 25, 2818-2826.
9. Chen L, Hu L, Chan TH, Tsao GS, Xie D, Huo KK et al. (2009) Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1 l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival. Hepatology 50, 122-129.
10. Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL et al. (2013) SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology 144(179-191), e174.
11. Murphy-Ullrich JE, Sage EH (2014) Revisiting the matricellular concept. Matrix Biol. 37, 1-14.
12. Tang L, Feng J (2014) SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target. Curr. Pharm. Des. 20, 6182-6190.
13. Yang C, Fischer-Keso R, Schlechter T, Strobel P, Marx A, Hofmann I (2015) Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression. Tumour Biol. 36, 9567-9577.
14. Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao Y et al. (2015) SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol. Cancer. 14, 12.
15. Miao L, Wang Y, Xia H, Yao C, Cai H, Song Y (2013) SPOCK1 is a novel transforming growth factor-beta target gene that regulates lung cancer cell epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun. 440, 792-797.
16. Kubelt C, Hattermann K, Sebens S, Mehdorn HM, Held-Feindt J (2015) Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas. Int. J. Oncol. 46, 2515-2525.
17. Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A (2012) 'Go or grow': the key to the emergence of invasion in tumour progression? Math. Med. Biol 29, 49-65.
18. Mu Q, Wang L, Yu F, Gao H, Lei T, Li P et al. (2015) Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. Cancer Biol. Ther. 16, 623-633.
19. Hemmings BA (1997) Akt signaling: linking membrane events to life and death decisions. Science 275, 628-630.
20. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
21. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644.
22. Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang E et al. (2013) Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma. Cell Death Dis. 4, e634.
23. Kong L, Schafer G, Bu H, Zhang Y, Klocker H (2012) Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. Carcinogenesis 33, 751-759.
24. Ha GH, Park JS, Breuer EK (2013) TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett. 332, 63-73.
25. Gill RM, Gabor TV, Couzens AL, Scheid MP (2013) The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation. Mol. Cell. Biol. 33, 498-513.